Search results for "Salami"

showing 10 items of 28 documents

Porta orientale, Parma. Limen urbano e sguardo infinito

2011

Il contributo fa riferimento alla presentazione del progetto di Andrea Sciascia, "Porta orientale, Parma", nell'ambito del 9° Convegno nazionale ad inviti "Identità dell’Architettura Italiana", svoltosi presso l'Università degli Studi di Firenze, Dipartimento di Architettura. Il progetto propone una grande piastra solcata trasversalmente da un’area verde, che costituisce l’elemento ordinatore del disegno generale nella rilettura delle tracce del paesaggio rurale governato dalla memoria delle tracce della centuriazione. La piastra ritrova la sua unità solo lungo il fronte della via Emilia, dove una torre sottolinea l’angolo sul bordo sud-est del recinto dell’area ex Salamini. È questo un pun…

Limite soglia città campagna Parma area ex SalaminiSettore ICAR/14 - Composizione Architettonica E Urbana
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

2019

[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water at an acidic and a neutral pH show negligible dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is added because of hydrolysis of an azo bond in the capping ensemble. Additionally, olsalazine fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the colon. In vivo pharmacokinetic studies in rats show …

MaleHydrocortisoneTECNOLOGIA DE ALIMENTOSReducing agentPharmaceutical Science02 engineering and technologyMesoporous silica microparticles030226 pharmacology & pharmacyInflammatory bowel diseaseSodium dithionite03 medical and health scienceschemistry.chemical_compoundHydrolysisDrug Delivery Systems0302 clinical medicineQUIMICA ORGANICAIn vivoDrug DiscoveryQUIMICA ANALITICAmedicineRhodamine BAnimalsGated materialsRats WistarMesalamineOlsalazineRhodaminesColon targeted releaseQUIMICA INORGANICAMesoporous silicaColitisInflammatory Bowel DiseasesSilicon Dioxide021001 nanoscience & nanotechnologySmart drug delivery materialsRatschemistryDrug deliveryMolecular Medicine0210 nano-technologymedicine.drugNuclear chemistry
researchProduct

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

2016

Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 pati…

MaleSettore MED/07 - Microbiologia E Microbiologia Clinicaved/biology.organism_classification_rank.specieslcsh:MedicineGastroenterologyInflammatory bowel diseaselaw.inventionProbioticchemistry.chemical_compound0302 clinical medicineLactobacillus acidophiluslawMesalamineBifidobacteriumSettore MED/12 - GastroenterologiabiologyLactobacillus salivariusMicrobiotaMedicine (all)Anti-Inflammatory Agents Non-Steroidalfood and beveragesMiddle AgedUlcerative colitisLactobacillus acidophilusTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleBifidobacteria; Inflammatory bowel diseases; Lactobacilli; Microbiota; Ulcerative colitis; Medicine (all); Biochemistry Genetics and Molecular Biology (all)Adultmedicine.medical_specialtyCombination therapyinflammatory bowel diseasesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMesalazineDouble-Blind MethodBifidobacteriaInternal medicinemedicineHumansulcerative colitisAgedAnalysis of VarianceBifidobacterium bifidumUlcerative colitiBiochemistry Genetics and Molecular Biology (all)ved/biologybusiness.industryProbioticslcsh:Rbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia GeneralechemistryLactobacilliLigilactobacillus salivariusColitis UlcerativeBifidobacterium bifidumbusiness
researchProduct

Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

2007

Background and aims: increased epithelial cell proliferation may be detected in diverticular disease, but antibiotics have failed in reducing it. We assess therefore the effect of mesalazine on epithelial cell proliferation in diverticular disease. Methods: a prospective study was conducted on 20 consecutive patients with a new endoscopic diagnosis of symptomatic uncomplicated diverticular disease. The patients were treated with mesalazine 1.6 mg/day for 1 year. The Ki-67 antigen index of the whole crypt and in the upper third was separately evaluated before and after starting the treatment. Results: cell proliferation index was higher in diverticular disease patients than healthy controls …

Malediverticular diseaseSeverity of Illness IndexGastroenterologychemistry.chemical_compoundReference ValuesProspective StudiesIntestinal MucosaMesalamineProspective cohort studyCell proliferationtreatmentmedicine.diagnostic_testAnti-Inflammatory Agents Non-SteroidalBiopsy Needledigestive oral and skin physiologyGastroenterologyColonoscopyMiddle AgedImmunohistochemistryDiverticulosisDose–response relationshipTreatment OutcomemesalazineDiverticular diseaseFemalemedicine.medical_specialtyCryptRisk Assessmentdigestive systemDrug Administration ScheduleStatistics NonparametricMesalazineInternal medicineBiopsyDiverticulosis ColonicmedicineHumansAgedProbabilityDose-Response Relationship DrugHepatologybusiness.industryCase-control studyEpithelial Cellsmedicine.diseasedigestive system diseasescolonic mucosaKi-67 AntigenchemistryCase-Control StudiesbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats

2011

5-Aminosalicylic acid (5-ASA) loaded N-Succinyl-chitosan (SucCH) microparticle and freeze-dried system were prepared as potential delivery systems to the colon. Physicochemical characterization and in vitro release and swelling studies were previously assessed and showed that the two formulations appeared to be good candidates to deliver the drug to the colon. In this work the effectiveness of these two systems in the treatment of inflammatory bowel disease was evaluated. In vitro mucoadhesive studies showed excellent mucoadhesive properties of both the systems to the inflamed colonic mucosa. Experimental colitis was induced by rectal instillation of 2,4,6-trinitrobenzene sulfonic acid (TNB…

Malemedicine.medical_specialtyAminosalicylic acidColonPolymersPharmaceutical ScienceLymphocyte ActivationInflammatory bowel diseaseGastroenterologyAbsorptionChitosanchemistry.chemical_compoundDrug Delivery SystemsIn vivoInternal medicinemedicineAnimalsIntestinal MucosaRats WistarMicroparticleColitisMesalaminePeroxidaseChitosanDrug CarriersChemistryAnti-Inflammatory Agents Non-SteroidalOrgan SizeColitismedicine.diseasedigestive system diseasesIn vitroRatsDisease Models AnimalFreeze DryingTrinitrobenzenesulfonic AcidSwellingmedicine.symptomInternational Journal of Pharmaceutics
researchProduct

Inflammatory bowel disease in patients over the age of 70y. Does the disease duration influence its behavior?

2018

Introduction: The fastest growing segment of our population is that of people above 70 years of age. Elderly patients with IBD exhibit several specific problems. Our objective was to evaluate the clinical course, the side effects of the treatments and the need for surgery of elderly patients, regardless of the age of onset.Materials and Methods: This was a cross-sectional study wherein retrospective data were collected from multiple centers from seven hospitals within the Valencia metropolitan area. Data were collected on patients older than 70y with inflammatory bowel disease.Results: We identified a total of 331 patients older than 70 years of age (5.3% of patients monitored at our center…

Malemedicine.medical_specialtyDisease durationPopulationComorbiditymacromolecular substancesInflammatory bowel diseaseGastroenterology03 medical and health sciencesElderly0302 clinical medicineAdrenal Cortex HormonesNeoplasmsInternal medicinemedicineHumansImmunologic FactorsIn patientMesalamineeducationAgedRetrospective Studiesulcerative colitisAged 80 and overCrohn's diseaseeducation.field_of_studybusiness.industrymusculoskeletal neural and ocular physiologyGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisCrohn's diseaseCross-Sectional StudiesLogistic ModelsSpainSurgical Procedures Operative030220 oncology & carcinogenesisDisease ProgressionFemale030211 gastroenterology & hepatologybusiness
researchProduct

Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications

2019

Enteric coatings have shown in vivo dissolution rates that are poorly predicted by traditional in vitro tests, with the in vivo dissolution being considerably slower than in vitro. To provide a more mechanistic understanding of this, the dependence of the release properties of various enteric-coated (EC) products on bulk pH and bicarbonate molarity was investigated. It was found that, at presumably in vivo-relevant values, the bicarbonate molarity is a more significant determinant of the dissolution profile than the bulk pH. The findings also indicate that this steep relationship between the dissolution of enteric coatings and bicarbonate molarity limits those coatings' performance in vivo.…

Molar concentrationChemistry PharmaceuticalBicarbonateInorganic chemistryKineticsPharmaceutical ScienceCapsules02 engineering and technologyBuffers030226 pharmacology & pharmacyExcipientsDiffusion layer03 medical and health scienceschemistry.chemical_compoundHypromellose Derivatives0302 clinical medicineIntestine SmallmedicineHumansIntestinal MucosaMesalamineDissolutionAcetaminophenCarbonic acidGeneral MedicineHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEnteric coatingBicarbonatesDrug LiberationModels ChemicalSolubilitychemistryCarbon dioxide0210 nano-technologyBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic …

2011

In an earlier work, the role of heat shock protein (Hsp60) in the pathogenesis of ulcerative colitis (UC) was suggested by its significant increase in the pathological mucosa parallel with an increase in inflammatory cells. More data in this direction are reported in this work. We analyzed by immunohistochemistry biopsies of colon tissue from 2 groups of patients with UC and treated with either 5-aminosalicylic acid (5-ASA) alone or in combination with a probiotic. We looked for inflammatory markers and Hsp60. Both the treatments were effective in reducing symptoms but the group treated with both 5-ASA and probiotics showed better clinical results. Amelioration of symptoms was associated wi…

Pathologymedicine.medical_specialtyHistologyColonBiopsyAntigens Differentiation MyelomonocyticInflammationBiomarkers PharmacologicalPathology and Forensic MedicinePathogenesisAntigens CDHeat shock proteinmedicineHumansColitisMesalamineInflammationMucous Membranebusiness.industryCD68ProbioticsAnti-Inflammatory Agents Non-SteroidalColocalizationChaperonin 60medicine.diseaseUlcerative colitisImmunohistochemistryMedical Laboratory TechnologyProtein TransportGene Expression RegulationDisease ProgressionImmunohistochemistryColitis Ulcerativemedicine.symptombusinessFollow-Up StudiesApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

2007

Inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis are the result of an imbalanced mucosal T cell response. Despite the identification of a genetic susceptibility region in the NOD2/CARD15 (nucleotide-binding oligomerisation domain 2/caspase recruitment domain 15) gene, the aetiology is still unclear. Thus, the hunt for disease-initiating factors such as defects in the mucosal barrier or pathogenic microorganisms is ongoing. By contrast, the immunopathogenesis in IBDs is better understood. The identification of cytokines that are involved in T cell and monocyte signalling led to specific therapeutic concepts. Recent data have clearly shown that the most powerf…

Programmed cell deathNecrosisCell Survivalmedicine.medical_treatmentT cellT-LymphocytesApoptosisImmune systemCrohn DiseaseNOD2AzathioprinemedicineHumansIntestinal MucosaMesalamineImmunity Mucosalbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaAnti-Inflammatory Agents Non-SteroidalGastroenterologyRecent Advances in Basic ScienceInflammatory Bowel DiseasesInterleukin-12Immunosuppressive drugmedicine.anatomical_structureApoptosisImmunologyTumor necrosis factor alphamedicine.symptombusinessImmunosuppressive AgentsSignal TransductionGut
researchProduct